Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Selected Sarcoma Subtypes
NCT02048371Phase 2Completed
- Sponsor
- Sarcoma Alliance for Research through Collaboration
- Start
- Jul 2014
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in Liposarcoma, osteosarcoma (OS), Ewing sarcoma, rhabdomyosarcoma (RMS), mesenchymal chondrosarcoma (MCS), sponsored by Sarcoma Alliance for Research through Collaboration. Started Jul 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
Liposarcomaosteosarcoma (OS)Ewing sarcomarhabdomyosarcoma (RMS)mesenchymal chondrosarcoma (MCS)
Beyond the preview
Go deeper on NCT02048371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02048371.